Biogen Inc. (BIIB) Sees a More Significant Dip Than Broader Market: Some Facts to Know
In the latest trading session, Biogen Inc. (BIIB) closed at $263.43, marking a -1.6% move from the previous day.
Biogen Inc. (BIIB) Stock Declines While Market Improves: Some Information for Investors
The latest trading day saw Biogen Inc. (BIIB) settling at $260.58, representing a -0.52% change from its previous close.
Healthcare Heroes: 3 Stocks Innovating in Medicine and Wellness
The United States leads globally in the healthcare sector, with its innovative healthcare stocks drawing attention from an impressive $4.3 trillion in spending. As the American Medical Association ...
Top 3 Healthcare Stock Picks for the New Year
After lagging most sectors in 2023, healthcare stocks could deliver substantial returns in 2024. The market has been overly pessimistic about the sector due to short-term challenges.
Election noise may make pharmaceutical stocks 'untenable' for investors, says Mizuho's Jared Holz
Jared Holz, Mizuho healthcare sector specialist, joins 'The Exchange' to discuss the 2024 outlook for health care, which stocks to buy in the new year, and more.
Biogen ‘welcomes' EC decision to revoke CMAs for generic versions of Tecfidera
Biogen Inc. BIIB, +0.89% said Tuesday that the European Commission has revoked the centralized marketing authorizations for generic versions of the biotechnology company's multiple sclerosis treatm...
Mind-Bending Growth: 3 Psychedelic Stocks With Trippy Potential
Mental health has been one of the hot topics in the medical industry over the past few years. Widespread awareness was brought to the public eye during the COVID-19 pandemic as people in prolonged ...
Why Is Biogen Inc. (BIIB) Up 6.4% Since Last Earnings Report?
Biogen Inc. (BIIB) reported earnings 30 days ago. What's next for the stock?
Biogen: LAQEMBI's $10 Billion Potential
Biogen's latest Alzheimer's drug, Aduhelm, faced challenges after FDA approval, leading to concerns about efficacy and high costs. Biogen and Eisai's latest FDA-approved lecanemab faces similar ris...
Biogen Inc. (BIIB) Evercore ISI 6th Annual HealthCONx Conference (Transcript)
Biogen Inc. (NASDAQ:BIIB ) Evercore ISI 6th Annual HealthCONx Conference November 28, 2023 9:10 AM ET Company Participants Priya Singhal - Head of Development Conference Call Participants Umer Raff...
The Alzheimer's Drug Market Is Heating Up. Should You Buy the Leading Contenders' Stocks?
There's now more than one medicine on the market to treat Alzheimer's disease. Safety and efficacy will be the two major areas of future competition.
Biogen lowers full-year earnings guidance, 3Q revenue beats expectations
Biogen Inc (NASDAQ:BIIB) revised its full-year earnings guidance downward due to acquisition-related costs following the company's $7.3 billion bid for Reata Pharmaceuticals in July. The firm said ...
Biogen Inc. (BIIB) Q3 2023 Earnings Call Transcript
Biogen Inc. (NASDAQ:BIIB ) Q3 2023 Results Earnings Conference Call November 8, 2023 8:00 AM ET Company Participants Chuck Triano - Head of Investor Relations Christopher Viehbacher - President and...
Biogen (BIIB) Beats on Q3 Earnings & Sales, Cuts EPS View
Biogen (BIIB) beats third-quarter estimates for earnings and sales. It lowers its 2023 EPS guidance range to include the impact of dilution from the Reata acquisition.
Biogen quarterly results top estimates despite complex launch of new Alzheimer's treatment
Biogen Inc. BIIB, -1.21% on Wednesday reported third quarter results that topped analyst estimates, even as it navigates a complex launch of its new Alzheimer's treatment Leqembi.
Related Companies